AUTHOR=Yan Ningning , Zhang Ziheng , Guo Sanxing , Shen Shujing , Li Xingya 

TITLE=Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report

JOURNAL=Frontiers in Medicine

VOLUME=Volume 10 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1130012

DOI=10.3389/fmed.2023.1130012

ISSN=2296-858X

ABSTRACT=Objective: Current treatment agents for liver cancer are mostly immune checkpoint inhibitors (ICI) and multitarget tyrosine kinase inhibitors (TKIs); however, their limited overall response rate and shorter median progression-free survival (PFS) discourage their frequent use. The development of Mesenchymal Epithelial Transition Factor (MET) Tyrosine Kinase Inhibitors (MET-TKI) has transformed the treatment pattern in MET-altered solid tumors altered with MET and improved their prognosis. However, the benefits of MET-TKIs in MET-amplified liver cancer remain unclear. 
Methods: Here, we present a case of advanced liver cancer amplified with MET treated with savolitinib, a MET-TKI, after progression from first-line treatment with bevacizumab plus sintilimab. 
Results: The patient achieved a partial response (PR) to savolitinib in the second line setting. The progression-free survival (PFS) of first-line of bevacizumab plus sintilimab and sequential second-line treatment with MET-TKI, savolitinib, are 3 and over 8 months, respectively. furthermore, the patient still had continuous PR status with manageable toxicities. 
Conclusions The present case report provides first-hand evidence that savolitinib may be beneficial for patients with advanced MET-amplified liver cancer and offers a promising treatment option.